Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4405094 · 2 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| LY4405094 Study AT01 (Healthy ISA) | EXPERIMENTAL | LY4405094 or placebo administered intravenously (IV) or subcutaneously (SC) in healthy volunteers. |
| LY4405094 Study AT01 (AD ISA) | EXPERIMENTAL | LY4405094 or placebo administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid positron emission tomography (PET) scan. |
| LY4405094 Part A: Single-Ascending Dose (SAD) | EXPERIMENTAL | LY4405094 administered intravenously (IV) or subcutaneously (SC) in healthy volunteers. |
| Placebo Part A | PLACEBO_COMPARATOR | Placebo administered IV or SC in healthy volunteers. |
| LY4405094 Part B: Multiple Ascending Dose (MAD) | EXPERIMENTAL | LY4405094 administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid positron emission tomography (PET) scan. |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid positron emission tomography (PET) scan. |
| Name | Type | Description |
|---|---|---|
| LY4405094 | DRUG | Administered intravenously (IV) |
| Placebo | DRUG | Administered IV |
| Florbetapir F18 | OTHER | Administered IV |
| Florbetaben F 18 | OTHER | Administered IV |
Participants must meet eligibility criteria below. Additional criteria are specified in the substudy to which the participant will enroll. Inclusion Criteria for Healthy Participants: * Are between 18 and 45 years of age * Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg...
Top 20 of 24 competitors
LY4405094 is an investigational small molecule being studied for the treatment of Alzheimer's disease and for use in healthy volunteers. It is being evaluated in early-stage clinical trials to assess its effects on amyloid plaques, which are associated with Alzheimer's disease.
LY4405094 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
LY4405094 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trials are designed to evaluate its safety, tolerability, and pharmacokinetics in healthy participants and those with Alzheimer's disease.
LY4405094 is being studied in two Phase 1 clinical trials. One trial, NCT07787169, is a master protocol studying multiple amyloid-targeting therapies in healthy participants and participants with Alzheimer's disease. Another trial, NCT07787182, is a dedicated study of LY4405094 in the same populations. Both trials are not yet recruiting and are based in the United States.
LY4405094 is designed to target amyloid, a protein that forms plaques in the brains of people with Alzheimer's disease. By targeting amyloid, the drug aims to reduce or clear these plaques, potentially slowing the progression of the disease. This mechanism is being investigated in early-stage clinical trials.
LY4405094 is a distinct investigational drug being developed by Eli Lilly. It is part of a master protocol that studies multiple amyloid-targeting therapies, but LY4405094 itself is a unique compound. No alternative names for LY4405094 have been disclosed in the clinical trial information.